Developing a vaccine to prevent lung cancer progression
Lung Cancer Vaccine
['FUNDING_OTHER'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-10906214
This study is testing a new RNA-based vaccine designed to help prevent non-solid lung nodules from turning into cancer, and it's for patients who have these nodules and might be interested in participating in future trials.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10906214 on ClinicalTrials.gov |
What this research studies
This research focuses on creating an RNA-based vaccine aimed at preventing the progression of non-solid lung nodules, which can develop into invasive adenocarcinoma. By analyzing the immune environment and tumor-associated antigens in these nodules, the study seeks to activate specific immune responses that could halt cancer development. Patients with detected non-solid nodules may be eligible for vaccination, which will be tested in preclinical models before moving to clinical trials. The approach involves advanced techniques such as lipo-nanoparticle RNA delivery to enhance vaccine efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with detected non-solid lung nodules that are at risk of progressing to invasive adenocarcinoma.
Not a fit: Patients with already diagnosed invasive lung cancer or those without non-solid nodules may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new preventive treatment option for patients at risk of developing invasive lung cancer.
How similar studies have performed: Other research has shown promise in using RNA-based vaccines for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIPKIN, STEVEN M — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: LIPKIN, STEVEN M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, Cancer Vaccines, CancerModel